Quest Diagnostics combines a nationwide laboratory moat, accelerating volume and advanced-testing growth, and strong cash returns, with PAMA reimbursement cuts the principal threat to its resilient compounding outlook.
Overview
Quest Diagnostics is an essential U.S. healthcare infrastructure provider, with its Diagnostic Information Services segment generating approximately 98% of consolidated revenue. Its catalog exceeds 3,500 assays, spanning routine clinical testing and advanced oncology, neurology, genetic, and molecular diagnostics. It serves one in three adult Americans and works with approximately half of U.S. physicians and hospital systems. Nationwide logistics, broad payor coverage, cost scale, and EHR integration support a co-duopoly position with Labcorp and meaningful switching costs. Q2 2026 revenue rose 10.2% to $3.043 billion, with 13.1% requisition growth offset partly by a 2.8% decline in revenue per requisition. Adjusted EPS increased 19.1% to $3.12, beating consensus by $0.30, and management raised 2026 revenue guidance to $11.95–$12.05 billion and adjusted EPS to $11.05–$11.25. At $230.44, DGX trades at about 20.4x FY2026E forward earnings and 12.2x LTM EV/EBITDA, with a 5.3% FCF yield and 1.5% dividend yield. **The investment case is resilient volume compounding plus advanced-test and consumer growth;** near-term catalysts include Q3 results, joint-venture execution, and continued growth in consumer and proprietary assays.